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In this article, Médicos Sin Fronteras (MSF) Spain faces the challenge of selecting, piecing together, and
conveying in the clearest possible way, the main lessons learnt over the course of the last seven years in the
world of medical care for Chagas disease. More than two thousand children under the age of 14 have been
treated; the majority of whom come from rural Latin American areas with difficult access. It is based on these
lessons learnt, through mistakes and successes, that MSF advocates that medical care for patients with Chagas
disease be a reality, in a manner which is inclusive (not exclusive), integrated (with medical, psychological,
social, and educational components), and in which the patient is actively followed. This must be a multi-disease
approach with permanent quality controls in place based on primary health care (PHC). Rapid diagnostic tests
and new medications should be available, as well as therapeutic plans and patient management (including side
effects) with standardised flows for medical care for patients within PHC in relation to secondary and tertiary
level, inclusive of epidemiological surveillance systems.
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Médicos Sin Fronteras (MSF) is a non-profit, non-govern-
mental humanitarian organization, which was created in
Paris in 1971 by a group of doctors and journalists (http:/
/www.msf.org). As stated in their Magna Carta, MSF pro-
vides assistance to populations in danger, to the victims
of natural or man-made disasters, and victims of con-
flict situations irrespective of race, religion, creed or
political affiliation. Every year more than 20,000 MSF
professionals from all over the world provide medical
attention to persons in need in more than 70 countries,
pledging themselves with respect to the deontological
rights of their profession and to remain completely in-
dependent from any political, economic or religious
power. All of this is possible thanks to more than three
million donors around the world.
In 1999 MSF was awarded the Nobel Peace Prize.
MSF dedicated the award for the creation of the Drugs
for Neglected Disease initiative (DNDi), collectively
with a further six insitutions from different countries:
the “Fundação Oswaldo Cruz”, Brazil; the Indian Coun-
cil of Medical Research; Ministry of Health, Malaysia;
the Kenya Medical Research Institute; “Institut Pasteur”,
France; and the World Health Organization (WHO) Spe-
cial Programme for Research and Training in Tropical
Diseases (TDR) (http://www.dndi.org). Officially founded
in 2003, DNDi is a non-profit initiative whose mission is
to investigate and develop medications for neglected
diseases which affect millions of people worldwide.
In 1999 MSF Spain also faced the challenge of work-
ing, for the first time, with patients with Chagas disease
in a difficult context; the months after hurricane Mitch
hit Honduras, between the 26th and 30th of October of
the previous year. Until today, three MSF sections:
France, Spain, and Belgium have worked directly in six
diagnosis and treatment projects in five Latin American
countries: Honduras, Nicaragua, Guatemala, Bolivia, and
Brazil. They have directly developed, as well, informa-
tion, education, and communication (IEC) components
and/or consultancy in three further Latin American coun-
tries (Argentina, Ecuador, and Colombia) and two cities
belonging to the European Union (Cayenne, French Gui-
ana, France, and Barcelona, Catalonia, Spain). In addi-
tion, MSF collectively with the Pan American Health
Organization (PAHO) produced the “Virtual medical
training course in the diagnosis, management and treat-
ment of Chagas disease” on the internet (http://www.
paho.org/Spanish/AD/DPC/CD/dch-curso-virtual-
msf.htm; http://www.msf.es/curso%5Fchagas/) and co-
organized three physical course editions in Honduras,
Bolivia, and Colombia.
In this report, MSF Spain wanted to select, sum-
marise, and transmit the main lessons learnt, through
mistakes and successes, in the multiple Chagas projects
in which MSF has collaborated with many other national
and international institutions (Albajar et al. 2007). Over
the course of the last seven years more than two thou-
sand children under the age of 14 have been diagnosed
and treated, the majority of which have come from rural
Latin-American areas with difficult access. An objec-
tive of this section is to make a brief analysis of the
status quo of medical care for Chagas disease in Latin
America and beyond that, the strengths and weaknesses,
challenges, and future perspectives including proposals
of action for the long and medium term.
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METHODOLOGY FRAMEWORK
For this research, three framework references were
analyzed in order to provide the basis of a systematic
analysis; (1) lessons learnt from previous diagnostic and
treatment projects; (2) the natural evolution of Chagas
disease in areas with high morbimortality; (3) PAHO/
WHO consensus documents.
The first part of the methodology framework selected
was to compile the lessons learnt from projects where
MSF have worked which included Chagas disease diag-
nosis and treatment. MSF’s projects for paediatric diag-
nosis and treatment were: Yoro – Yoro – Honduras, Es-
quipulas and Totogalpa – Matagalpa – Nicaragua, Olopa
– Chiquimula – Guatemala, Entre Ríos – O’Connor –
Tarija – Bolivia and Sucre – Chiquimula – Bolivia. The
latter included diagnosis and treatment for patients up
to 18 years of age. The authors also included experience
drawn from a project which aims to diagnosis acute
Chagas disease in the population of eight states in the
Amazonian region of Brazil which involved training labora-
tory staff to look for parasites whilst reading malaria slides.
It is significant that the different Chagas disease di-
agnosis and treatment projects were developed in six
different Latin-American municipalities; four in the
Amazon basin or Northern Hemisphere, in the called Try-
panosoma cruzi I and zymogene 3 territory, and two in the
T. cruzi II one (Anonymous 1999). All pilot projects, de-
veloped with permanent contact with national Chagas dis-
ease programs, became key demonstrative experiences.
For the systematic analysis of each project, two sets
of data were considered. The first included pre-existing
(or non-existing) elements around which the project was
formed: buildings, supplies, equipment, human re-
sources, and internal processes including flow-charts and
protocols. The second set included elements from the
project’s context: national legislation; social, economic,
and cultural determinants of health; relevant aspects of
policies at local council, regional or national level, as
well as information regarding medical services for Cha-
gas disease (also at the aforementioned levels).
The second section of the methodology was chosen
in respect to the natural evolution of Chagas disease;
using as a reference an area in Brazil with one of the
highest morbimortality, with patients presenting cardiac,
digestive, and neurological complications during the
chronic phase of the disease (Dias 1995). Based on the
results of a prospective cohort of patients, the sum of
the percentage of patients presenting the indeterminate
form (60%), mild cardiac form (15%), and mild diges-
tive form, represented 75% (minimum) of recorded
cases (Xavier 1999).
The third section was constituted by consensus docu-
ments from WHO/PAHO: “Etiologic Treatment of
Chagas disease” (PAHO 1998), “Chagas disease control”
(WHO 2002), “PAHO Consultation on Congenital
Chagas Disease, its Epidemiology and Management”
(PAHO 2004), and the joint  PAHO-MSF document
“PAHO/MSF Regional Consultation on the Organization
and Structure of Medical Care to infected/ill patients by
Trypanosoma cruzi (Chagas disease)”,  Montevideo
2005. The latter document, among other important state-
ments, stresses the need to “integrate patient manage-
ment as a regular and sustainable component, to the al-
ready existing activities of prevention, control, and dis-
ease surveillance for diseases in health systems (public,
private, and those of social security). It also recommends
that those affected  by Chagas disease be seen by a gen-
eral practitioner as close to their place of residence as
possible” (PAHO 2005).
ASSESSMENT OF MEDICAL CARE IN CHAGAS DIS-
EASE
The contents of the analysis are presented below and
summarised in seven sections: Primary Health Care, Sur-
veillance Systems, Access to Diagnosis and Treatment,
Health Systems at Three Levels, Other Health Systems,
Guidelines for Standardization, and Needs for the Future.
PRIMARY HEALTH CARE
One of the main conclusions of this article is that
medical care for Chagas patients should mainly be pro-
vided at a PHC level. According to the authors, the natu-
ral evolution of the disease is a key criteria for estab-
lishing medical care at primary level. Previously this has
occurred with diseases such as diabetes mellitus (DM),
hypertension, and more recently, human immunodefi-
ciency virus (HIV) infection. All of these diseases were
initially treated by a specialist and later incorporated into
PHC services throughout large areas of the world.
Medical care is classically organized in response to
the demand, however, following the recent municipal-
ization of health services and models such as the “fam-
ily doctor”, PHC services can potentially provide ser-
vices which focus on prevention (primary prevention of
the infection and secondary for disease development),
and adapt medical care for Chagas disease to local speci-
ficities, using different approaches based on geographic,
social, cultural or other specific characteristics.
To say that the priority for medical care has must given
to primary level services does not exclude the important
participation of the secondary and tertiary levels of care. It
is necessary to identify factors today which may hinder the
take over of medical care for Chagas disease as a part of
PHC, as well as the positive factors that made this change
possible for other diseases some years ago.
Historically it is worth mentioning that over the co-
urse of several decades, all available resources and plan-
ned activities targeted vector control and that with the
arrival of the HIV/AIDS pandemic, this focus was wid-
ened monitoring blood transfusions (Dias et al. 2002).
These two items, vector control and blood transfusion,
are planned at a national or regional level. Paradoxically,
the diagnosis and treatment of infected patients (who can
be treated) is carried out at municipal level, but this has
been delayed even in areas where vector control has been
successful.
Also of historic significance is the fact that the few
studies which attempted to demonstrate the effective-
ness of etiologic treatment were only made during the
last decade of the XX century, probably based on the
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time, proved that the parasite remained in the targeted
tissues, meaning they could no longer attribute the
etiopathogeny exclusively to immunological mecha-
nisms (James et al. 2002). Actually, the first study to
demonstrate the efficacy of treatment with benznidazole
in patients under 12 years of age was not produced until
the 1990s (Andrade et al. 1996, Sosa-Estani et al. 1998),
neither were the first studies, even though statistically
limited, which demonstrated a lower incidence of elec-
trocardiographic changes and less clinical development
in the group of treated patients (Viotti et al. 1994, 2006,
Villar 2002). At that moment, the significant geographi-
cal differences in the response to treatment were already
known and were probably related to the T. cruzi variety
as well as differences in the host, among others. WHO
quickly used these findings in two consensus documents;
one specifically concerning treatment (PAHO 1998) and
another about Chagas disease as a whole (WHO 2002)
which included very specific recommendations in the
treatment of patients under 12 years of age. This left the
criteria as to the decision regarding the pertinence of an
etiologic treatment in the adult patient in the hands of
the practitioner and patient. Despite these recommen-
dations, neither the diagnosis criteria nor the treatment
of patients under 12 years of age were systematically
incorporated into health systems in Latin America, prob-
ably due to a historic methodology which was embedded
in the training and refresher courses of practitioners both
during medical training and in post-graduate courses.
A decade later a group of researchers lead by Dr Rassi
and Dr Luquetti, in Goiás, Brazil, sounded the alert that
in South America confirmation of parasitological cure
with seroconversion, in those who had been infected for
less than a year, normally occurred within a year of com-
pleting ethiologic treatment; in those that were infected
for 10 to 15 years, seroconversion took place between
5 and 10 years after completing treatment; in those in-
fected for more than 20 years at least 10 years were
needed in order to verify parasitological cure (Luquetti
& Rassi 2002). This was most likely another reason which
demotivated practitioners to treat patients; owing to the
apparent lack of response to treatment or even to the
difficulty in explaining treatment efficacy to the patient
in the short term.
Another factor of historic significance was the fact
that Chagas was a cardiologist’s and/or “chagólogos”
disease, and not all cardiologists and/or echocardio-
graphists treated Chagas disease. Probably the limited
low efficacy spread around, the secondary effects, quan-
titatively and qualitatively significant (Castro et al. 2006),
and the fact that it was a disease not valued by many prac-
titioners (MSF 2005, Maguire 2006) were the main rea-
sons why the disease remained neglected. The complex-
ity of the disease and its natural evolution does not jus-
tify the exclusivity of medical care done by specialists
in this day and age. As an example, a cardiologist can
read an electrocardiogram (ECG), classify patient from
the cardiology point of view and make a prognosis from
the cardiac alterations found, but even in areas with high
morbidity only 15 to 20% of the patients would need to
be follow up by them.
SURVEILLANCE SYSTEMS
Everything discussed up to this point in relation to
medical care constitutes a proposal that aims to “centri-
fuge” the disease towards PHC. However, this strategy
must go hand in hand with another which needs to be
developed with the same intensity but which moves in
the opposite direction: an information system that goes
from primary health to the other levels of care (centrip-
etal). Worldwide all countries, including those in Latin
America, face this as one of their greatest challenges; to
install an epidemiological model of surveillance and
notification which would make real data and up-to-date
figures available in order to evaluate, decide, and plan
medical care, including budget planning. According to
the authors, national health information systems, vector
control strategies, and blood banks are examples of sys-
tems which ideally, must have a supra municipal struc-
ture and coordination at national or, at least regional level.
It is also the responsibility of governments to establish
technical and operational regulations, verification of
quality, registration, and acquisition of supplies on a large
scale, among others.
ACCESS TO DIAGNOSIS AND TREATMENT
Diagnosis is the access point to medical care, with-
out which the Chagas patient cannot receive medical at-
tention. There are at least four possible strategies for
diagnosis and consequent points of access to the health
system: (a) diagnosis in PHC with filter paper or rapid
diagnostic tests (Luquetti et al. 2003); (b) systematic
antenatal diagnosis, with screening and diagnosis of chil-
dren born from infected mothers (Russomando et al.
2005), allowing clinical evaluation and the etiologic and
non-etiologic treatment of pregnant women following
delivery; (c) confirmed diagnosis of people who were
tested  during blood bank screening; (d) clinical identi-
fication of acute symptomatic patients, including cases
of oral transmission, as well as chronic cases present-
ing with the different forms: cardiac, digestive, neuro-
logical, and even those with cerebral vascular accidents.
In the Amazon region, another potential entry point could
be the identification of T. cruzi in blood films prepared
for malaria diagnosis.
In this day and age, access to treatment represents
another challenge. Following the transfer of technology
made by the pharmaceutical company Roche to a public
laboratory (Lafepe) in Pernanbuco, Brazil. Lafepe is now
responsible for the short term production of benz-
nidazole for the rest of the world. Support by the PAHO
will be necessary to ensure quality control, registration,
and commercialization of this drug worldwide. It is nec-
essary to avoid delays in these processes in order to pre-
vent the drug being “out of stock” in countries where the
infection/disease is endemic.
In addition, pilot experiences (already presented at
international forums but not yet published in the treat-
ment of patients under 14 years of age) in countries such
as Honduras (MSF) and Colombia (National Health In-
stitute), found surprisingly high percentages of cure rates
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compared with studies carried out South of Amazonia.
These experiences encourage the replication of similar
projects in other regions as well as the expansion of ex-
periences to encompass other age groups.
HEALTH SYSTEMS AT THREE LEVELS
Regarding the different levels of health care, each
level has its own attributes.
In PHC, rapid diagnostic tests which could use whole
blood without requiring any additional instruments, such
as centrifuges, etc. are clearly needed. The objective
would be that nurses would perform the screening and
diagnostic confirmation, as with other health programs
such as diabetes. Ideally, two rapid tests with different
technique and different antigen detection would be used.
Until this is possible, the collection of samples using
filter paper will continue as an excellent method for
screening, even in areas with difficult geographic access.
At a medical level, it will be necessary for doctors
to be trained in taking a complete history and perform-
ing a correct physical examination with the objective of
detecting any clinical sign, in acute or chronic phases,
and to evaluate the stability or clinical progression of
the patient, this would include any reactivation due to
immunosuppression or any other cause. The presence
of cerebral vascular accidents originating from the car-
diac form of Chagas disease is another challenge that
should be addressed through proper clinical training prior
to graduation from university (Carod-Artal 2006).
With regards to complementary tests, it is unusual to
have the option of an ECG or even X-ray at PHC level.
When ever possible, clinical screening is particularly
important at this level. Assessment of whether an ECG
is normal or not will identify at least 60% of the inde-
terminate forms with an excellent prognosis (Sousa et
al. 2001). In a thoracic X-ray it is possible to evaluate
whether or not the cardiothoracic index is above normal
values. Chest X-ray (right anterior oblique) performed
60 s after swallowing the contrast medium should not
demonstrate a diameter exceeding 5 cm in the oesopha-
gus, nor a delay in oesophageal emptying following the
Rezende technique (Rezende & Moreira 1988). An ab-
dominal X-ray taken following the introduction by grav-
ity of 1200 ml of barium contrast and water (placed 1 m
above the table where the X-ray is being taken), should
not demonstrate loss in basal muscular tone; a colonic di-
latation  greater than 6 cm is also in accordance with the
Rezende technique (Rezende & Moreira 1988).
As with other chronic diseases such as tuberculosis
or leprosy, medical services require a more pro-active
approach with frequent visits to communities and homes
when necessary. Experience tells us that early detection
is the key to managing the secondary effects of benz-
nidazole and nifurtimox at PHC level and even to pre-
vent the majority of severe secondary effects. When
symptoms are mild and there are hospital services at
hand, patients can be managed by maintaining a minimum
therapeutic dose (5 mg/kg/day) and adding specific treat-
ment for each. When close follow-up of the patient is
not an option, and more importantly, when the patient
cannot contact the health facility or the practitioner if
emergency evacuation is necessary, the decision to ini-
tiate treatment should be carefully weighed up.
Regarding diagnosis and bearing in mind the aforemen-
tioned entry points, history taking, and physical examina-
tion, complementary ECGs and X-rays it is necessary to
create and have flow-charts available at the three levels of
care. One of the main challenges of the health system is to
improve referral and counter-referral procedures.
At secondary health care level, in the same way in
which laboratory tests confirm diagnosis in cases with
doubtful or inconclusive results (with possible discrep-
ancies between different diagnostic tests), it should be
possible to finalise clinical diagnosis in those patients
who were not diagnosed at PHC level. The management
of referred patients is essential to evaluate, for example,
the degree of cardiopathy and if specific cardiological
treatment is indicated. Likewise, this also applies to di-
gestive and neurological complications; it is necessary
to determine which clinical forms will need the special-
ist care and which patients could return to PHC level for
follow-up in the absence of major complications; which
could possibly be at least 75% of cases.
The second level referral and counter-referral pro-
cess has a unique opportunity to carry out quality con-
trol and to identify subjects for ongoing training at PHC
level; in the same way laboratories at secondary level
will organize quality control at primary level.
The second level would also be responsible for re-
ceiving those patients on treatment who present with
moderate to severe secondary effects requiring labora-
tory tests, complementary tests or specialist care in or-
der to recover. As examples, a haematologist may be re-
quired for a case of severe medullar depression or a neu-
rologist in event of severe or persistent neuritis.
The tertiary level should be responsible for those
clinical cases with cardiac, digestive or neurological
presentations of the disease, or with severe secondary
complications of treatment such as Steven-Johnson Syn-
drome. Even if these severe complications are rare, a ref-
erence and counter-reference system from primary and
secondary levels to tertiary level is vital for these patients.
Here again, as with the laboratory, the third level
should constitute part of the quality control of the sec-
ondary level as well as the ongoing training of profes-
sionals working at that level.
ANOTHER HEALTH SYSTEM
From everything discussed up to this point, and not
only exclusively in relation to  Chagas disease, it can be
deduced that we are advocating for a different health sys-
tem in order that the established medical system responds
to the needs of the population at risk, the infected and
ill, regarding prevention and medical care.
Health systems in Latin America and worldwide, will
have to carry out the necessary changes to be inclusive
of patients with Chagas disease. An exclusive system is
one, for example, that does not have diagnostic tests or
etiological treatment registered at national level.
A health system which had access to diagnosis and
treatment for Chagas disease, integrated and coexisting
within other health programs, would always be able to91 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 102(Suppl. I), 2007
provide a multi-disciplinary patient approach (Ehrenberg
& Ault 2005).
An integrated health system is required in which the
patient not only has access to medical care, but also to
psychological, social, and occupational components with
ongoing IEC at individual, family, and community level.
The IEC component should be a part of the actions pro-
grammed for the health system involving total collabo-
ration with the education system (Cabrera et al. 2003).
This is more evident, for example, when giving a posi-
tive result to a patient, above all in the called endemic
areas with evidence of other cases of the disease nearby
and deaths from the same cause. The anxiety or depres-
sion, social rejection, and discrimination in the workplace
which also infringes on national legislation, are all too fre-
quent in Latin America. On the other hand, the diagnosis of
Chagas infection may contribute to social discrimination
in countries where the illness has not been endemic.
Again, the need for the health system to have a sig-
nificant and ongoing interaction with the education sys-
tem is reiterated. This not only means the inclusion of
Chagas disease as a school subject, but the transforma-
tion of students into active participants in the surveil-
lance system; their role would involve the capture and
identification of possible vectors in homes and their
surroundings. In schools, as well, particularly in rural
areas with widespread populations, it is possible to pro-
vide etiological treatment in collaboration with a group
of teachers. With previous parental consent, over the
course of one academic year, one of the best diagnostic
and treatment interventions could be carried out at a cost
effective level.
 It should be emphasized that sustainability must be a
condition of any proposal at diagnostic, treatment, man-
agement or IEC levels. Bearing in mind that those af-
fected by Chagas disease are usually people with scarce
socioeconomic resources, this is more evident. If a pro-
posed measure bears an additional cost for the individual,
family or a community, there should at least be some
form of long or medium term economic return. Costly
interventions will only prove to be effective and con-
tinue if there is an improvement in the public health and
economy of the community.
GUIDELINES FOR STANDARDIZATION
In order that Chagas disease be incorporated, as any
other disease, in the health system of Latin American
countries and other territories in the world, it is neces-
sary to produce agreed-upon guidelines to help this be-
come a reality. A healthcare network should be estab-
lished from local council to national level, with clear
criteria. The active participation of the PAHO/WHO and
all those institutions who carry out similar identified
pilot projects will be essential. In order to produce these
guidelines, it will be necessary to bring together all of
the parties involved in decision-making; in addition to
the diagnostic and medical, economic, logistic and po-
litical components, among others. Cost effectivity analy-
sis is seen as one of the most important studies to assist
in decision-making. Sadly, until now this has rarely been
utilized for the diagnosis and treatment component.
This key fact has already been proven also in loca-
tions outside Latin America. When item 36 of the
Montevideo document literally specifies: “Countries
where Chagas disease/infection is not endemic which
receive migration from Latin American countries, should
establish a network of centres specialized in subjects
related to this infection, aiming to produce standards for
healthcare and control strategy protocols” (PAHO 2005).
The participation of the PHC system in these countries
has also been seen as necessary; not only in the effec-
tive medical care for at least 75% of patients, but also in
the agreement of protocols, monitoring strategies, the
IEC component of health personnel themselves and of
the target population: migrants, distributed through na-
tional territory, tourists from continents such as Europe
with destinations in Latin America-especially those with
greater prevalence and higher risk of exposure.
However, none of what has been discussed here would
be possible in reality without having the following es-
sential conditions in place.
Firstly, health professionals have to work, more than
ever, as a team (Ehrenberg & Ault 2005). A superior/
inferior relationship between doctors and nurses, spe-
cialists and generalists, people from urban and rural back-
grounds, among others, will make true interdisciplinary
work impossible. This project is only possible with profes-
sionals who are truly at the service of the health system.
Secondly, human resources need to be selected fol-
lowing technical and not political criteria. Unfortunately
the political system and local economic authorities have
often interfered, consequently damaging the quality of
care delivered to the population.
Thirdly, there must be a guarantee of continuity in
the human resources selected. Continuity is often lim-
ited to local political cycles, meaning no more than four
years. With the elections held every four years, particu-
larly at municipal level, employees are renewed and the
training of newcomers must be organized and repeated
all over again. Another reason for the high turn-over of
health professionals is the difficulty for doctors and
nurses working in rural areas to be up-dated and to par-
ticipate in refresher courses; this factor combined with
job stability would provide them with a career plan (Gil
2005). These are all significant issues in diseases such
as Chagas which require medium and long term planning.
Fourthly, the ultimate goal of health workers should
be the patient and not the health system itself. The de-
velopment of wealthy Western societies has brought with
it the organization and regulation of medical care to the
minutest detail; the negative side being that health staff
may focus more on following written rules rather than
providing adequate care to meet the needs of the patient.
Another risk, resulting from the current administrative,
working, and economic organization of health services,
is that health workers are more concerned with pleasing
their managers, or even in achieving their institutional
goals to ensure job security or getting variable parts of
their salaries linked to annual objectives, rather than pro-
viding true and quality medical care (Hunter 1998).
Fifthly and finally, the set of values of the Western
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quantity and quality response of the health system ac-
cording to the real individual and collective service given
more than to political or economical parameters. This
fact is particularly evident when analyzing neglected dis-
eases. Research and development of new diagnostic tests
and drugs for the etiologic treatment of Chagas disease
has almost been non-existent when compared with other
infectious diseases such as AIDS. Benznidazole and
nifurtimox, the only two drugs available for treatment,
have been in the market for more than 30 years and the
pharmacokinetic characteristics, formulations, efficacy,
and secondary effects are far from ideal.
There are two “external” systems which have inter-
fered with the health system: the political and economic
one. The need exists for a more autonomous health sys-
tem which could truly guarantee universal medical care
of acceptable quality.
NEEDS FOR THE FUTURE
In order to continue changing the status quo it is
necessary to become involved today in new challenges
that will influence tomorrow’s health services.
The marketing of new rapid diagnostic tests with good
sensitivity and specificity in the different T. cruzi terri-
tories is required. A great geographical diversity exists,
not only between the large territories of T. cruzi II, T.
cruzi I and zymodeme 3, but also within countries them-
selves; such as in the Amazon where the number of po-
tential co-infections and cross-reactions increases the
challenge to maintain a good positive and negative pre-
dictive value.
There is a need to market new rapid diagnostic tests
using antigens such as TESA, using the human infective form
of the parasite (trypomastigote) achieving higher sensitiv-
ity and specificity and being able to diagnose patients in
the acute phase of the infection (Umezawa et al. 1996).
A paediatric formulation for benznidazole and nifur-
timox is required. For more than 30 years we have been
breaking the 100 mg tablets and mixing them with all
kinds of liquids in order to administer them in paediat-
ric patients. In this day and age this practice is unaccept-
able and a solution should be provided from the pharma-
ceutical industry.
There is a need for new drugs with fewer secondary
effects and higher trypanomicidal activity. The advance-
ment in studies with posaconazole, already commercial-
ized for systemic mycotic infections, and ravuconazole, in
the animal experimental phase, is urgent. These are two
promising drugs for the mid and long term respectively.
Finally, the authors would like to state that the main
conclusion of their analysis is that nowadays, even with
the endless list of tasks for urgent development in the
health sector, after multiple pilot experiences in differ-
ent settings in Latin America; with the same tools that
were available at the beginning of this century, the diag-
nosis and treatment of Chagas disease is possible, neces-
sary, and from the ethical point of view, unquestionable.
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